1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside | 421592-30-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside
• 英文别名: 4-[(2-fluoro-4-methoxyphenyl)methyl]-1-isopropyl-5-methyl-1H-pyrazole-3-O-β-D-glucopyranoside；4-(2-fluoro-4-methoxy-benzyl)-1-isopropyl-5-methyl-3-β-D-glucopyranos-1-yloxy-1H-pyrazole；beta-D-Glucopyranoside,4-((2-fluoro-4-methoxyphenyl)methyl)-5-methyl-1-(1-methylethyl)-1H-pyrazol-3-yl；(2S,3R,4S,5S,6R)-2-[4-[(2-fluoro-4-methoxyphenyl)methyl]-5-methyl-1-propan-2-ylpyrazol-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 421592-30-5
• 化学式: C₂₁H₂₉FN₂O₇
• 分子量: 440.469
• InChiKey: AOBLNYCSGWSIPG-YRIDSSQKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-(2,3,4,6-O-tetraacetyl)-β-D-glucopyranoside 在 potassium tert-butylate 乙醇 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 15.0h， 生成 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside
  参考文献：
  名称：

  Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes

  摘要：

  本发明涉及制备一般式I化合物的方法，其中基团R1至R6和R7a、R7b、R7c根据权利要求1中的定义。此外，本发明涉及制备上述方法中的底物和中间体的方法，以及中间体本身。

  公开号：

  US20080020987A1

文献信息

• Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives
  申请人：Himmelsbach Frank

  公开号：US20070072813A1

  公开（公告）日：2007-03-29

  The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种预防或治疗代谢性疾病的方法，改善血糖控制，预防从糖耐量受损、胰岛素抵抗和/或代谢综合征进展到2型糖尿病，预防或治疗糖尿病并发症，减轻体重，预防或治疗胰岛β细胞退化，治疗高胰岛素血症和胰岛素抵抗以及1型糖尿病，方法是通过给需要的患者口服含有在权利要求1中定义的吡唑烷-O-糖苷或其前药或其药学上可接受的盐的药物组成物。
• Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-beta-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments
  申请人：Kraemer Gerd

  公开号：US20070244176A1

  公开（公告）日：2007-10-18

  The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

  本发明涉及1'-(异丙基)-4'-[(2-氟-4-甲氧基苯基)甲基]-5'-甲基-1H-吡唑-3'-O-β-D-葡萄糖苷的一种晶体形式，以及其制备方法，以及用于制备药物的使用。
• PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE
  申请人：Pinnetti Sabine

  公开号：US20100317575A1

  公开（公告）日：2010-12-16

  The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  本发明涉及一种制药组合物，包括根据权利要求1所述的化合物（1）至（29）中选择的吡唑-O-葡萄糖苷衍生物，与至少一种第二治疗剂的组合物，该第二治疗剂适用于治疗或预防选择自1型糖尿病、2型糖尿病、糖耐量受损和高血糖等一个或多个疾病。此外，本发明还涉及预防或治疗代谢紊乱及相关疾病的方法。
• CRYSTALLINE FORM OF 1' -(1-METHYLETHYL)-4' -[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5' -METHYL-1H-PYRAZOL-3' -O-BETA-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
  申请人：KRAEMER Gerd

  公开号：US20090181905A1

  公开（公告）日：2009-07-16

  The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

  本发明涉及1'-(1-甲基乙基)-4' -[(2-氟-4-甲氧基苯基)甲基]-5'-甲基-1H-吡唑-3'-O-β-D-葡萄糖苷的晶体形式，其制备方法以及用于制备药物的使用。
• New pyrazole derivatives and diabetic medicine containing them
  申请人：Ajinomoto Co., Inc.

  公开号：EP2163555A1

  公开（公告）日：2010-03-17

  The invention provides a pyrazole derivative of formula 1A or 1B which is useful in treating diabetes: wherein X represents a β-D-glucopyranosyl group, of which one or more hydroxyl groups may be acylated or β-D-glucuronyl group, of which one or more hydroxyl groups may be acylated and carboxyl group may be esterified; Y represents a lower alkyl group or perfluoro lower alkyl group; Z represents a hydrogen atom, lower alkyl group, perfluoro lower alkyl group, aralkyl group or phenyl group; R1 to R5 may be the same or different and represent a hydrogen atom, lower alkyl group, perfluoro lower alkyl group, lower alkoxy group, perfluoro lower alkoxy group, lower alkylthio group, perfluoro lower alkylthio group, lower alkyl amino group, halogeno group, lower alkanoyl group, lower alkenyl group or lower alkynyl group, and n represents an integer from 0 to 3; wherein the term "lower" indicates 1 to 6 carbon atoms.

  本发明提供了一种可用于治疗糖尿病的式 1A 或 1B 的吡唑衍生物： 其中X代表β-D-吡喃葡萄糖基，其中一个或多个羟基可被酰化，或代表β-D-葡萄糖醛酸基，其中一个或多个羟基可被酰化，羧基可被酯化；Y代表低级烷基或全氟低级烷基；Z代表氢原子、低级烷基、全氟低级烷基、芳基或苯基；R1 至 R5 可以相同或不同，代表氢原子、低级烷基、全氟低级烷基、低级烷氧基、全氟低级烷氧基、低级烷硫基、全氟低级烷硫基、低级烷基氨基、卤素基、低级烷酰基、低级烯基或低级炔基，n 代表 0 至 3 的整数；其中 "低级 "一词表示 1 至 6 个碳原子。